IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.080
+0.020 (1.89%)
At close: Oct 19, 2026, 4:00 PM EDT
1.090
+0.010 (0.93%)
After-hours: Oct 19, 2026, 6:53 PM EDT
IceCure Medical Revenue
IceCure Medical had revenue of $907.00K in the quarter ending June 30, 2026, with 72.76% growth. This brings the company's total for the last twelve months to $3.95M, up 41.62% year-over-year. In the year 2025, IceCure Medical had annual revenue of $3.38M with 2.67% growth. That makes IceCure Medical the 40,690th largest company in the world by revenue and 5,449th in the United States.
Revenue (ttm)
$3.95M
Revenue Growth
+41.62%
P/S Ratio
1.25
Revenue / Employee
$57,203
Employees
69
Market Cap
5.01M
Revenue by Geography
- Other 1.94M 57.3%
- United States 908.00K 26.9%
- Japan 282.00K 8.3%
- India 120.00K 3.6%
- China 108.00K 3.2%
- Israel 24.00K 0.7%
Fiscal year ended Dec 31, 2025 See the full IceCure Medical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.38M | 88.00K | 2.67% |
| Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | 2.21M | 132.75% |
| Dec 31, 2019 | 1.66M | 581.64K | 53.84% |
| Dec 31, 2018 | 1.08M | 389.12K | 56.30% |
| Dec 31, 2017 | 691.11K | 65.85K | 10.53% |
| Dec 31, 2016 | 625.25K | -139.86K | -18.28% |
| Dec 31, 2015 | 765.11K | -302.14K | -28.31% |
| Dec 31, 2014 | 1.07M | 711.63K | 200.11% |
| Dec 31, 2013 | 355.62K | 60.86K | 20.65% |
| Dec 31, 2012 | 294.76K | 189.18K | 179.17% |
| Dec 31, 2011 | 105.58K | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Trinity Biotech | 43.79M |
| Biomerica | 4.34M |
| Intelligent Bio Solutions | 4.22M |
| Axonex AI Group | 2.29M |
| 20/20 Biolabs | 2.04M |
| Co-Diagnostics | 721.39K |
| Phaos Technology Holdings (Cayman) Limited | 103.68K |
ICCM News
- 6 days ago - IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026 - PRNewsWire
- 13 days ago - IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site - PRNewsWire
- 20 days ago - IceCure Medical management to meet with Lake Street - TheFly
- 5 weeks ago - IceCure Medical granted regulatory approval to market ProSense in China - TheFly
- 5 weeks ago - IceCure Medical Receives Regulatory Approval to Market ProSense® in China - PRNewsWire
- 1 month ago - IceCure Medical announces distribution agreement with Scovas Medical - TheFly
- 1 month ago - IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands - PRNewsWire
- 2 months ago - IceCure Medical’s study for ProSense cryoablation approved by West Cancer Center - TheFly